Olema Pharmaceuticals (OLMA): Price and Financial Metrics
OLMA Price/Volume Stats
| Current price | $6.10 | 52-week high | $16.77 |
| Prev. close | $5.79 | 52-week low | $5.56 |
| Day low | $5.69 | Volume | 1,282,100 |
| Day high | $6.21 | Avg. volume | 770,596 |
| 50-day MA | $10.20 | Dividend yield | N/A |
| 200-day MA | $11.40 | Market Cap | 349.52M |
OLMA Stock Price Chart Interactive Chart >
Olema Pharmaceuticals (OLMA) Company Bio
Olema Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of targeted therapies for women's cancers. The company also focuses on OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD) that is being studied in a Phase 1/2 clinical trial for the treatment of metastatic or locally advanced ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema Pharmaceuticals was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA.
OLMA Price Returns
| 1-mo | -22.49% |
| 3-mo | -55.28% |
| 6-mo | -48.65% |
| 1-year | -55.73% |
| 3-year | -36.06% |
| 5-year | N/A |
| YTD | -56.52% |
| 2023 | 472.65% |
| 2022 | -73.82% |
| 2021 | -80.53% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...